However, with Eli Lilly's valuation at around $900 billion today, expectations are also sky-high. That can make it difficult ...

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...

LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.

Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade. The weight loss drug market is ...

Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings. The Earnings ...

Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...